Skip to content

Effects of intravenous antibiotics on gut microbiota and drug-resistance genes in critically ill patients

Effects of intravenous antibiotics on gut microbiota and drug-resistance genes in critically ill patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043469
Enrollment
Unknown
Registered
2021-02-19
Start date
2021-02-18
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critical illness

Interventions

Infected patients admitted to ICU and receiving intravenous antibiotics vs. Healthy individuals who did not receive antibiotic treatment.:Nil

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The case group and control group designed for this project are: 1. Infected patients admitted to ICU and receiving intravenous antibiotics; 2. Healthy individuals who did not receive antibiotic treatment. The inclusion criteria for the case group are as follows: (1) Patients who have been in ICU for more than 1 week and have not been hospitalized within half a year prior to this admission (aged over 18 years); (2) Intravenous antibiotics have been given for more than 1 week, and there is no oral and nasogastric tube antibiotic treatment. (3)No antibiotics (oral, intravenous, nasogastric tube, etc.) have been used in the six months before this study. The inclusion criteria of the control group are as follows: (1) In healthy individuals aged 18 years or above, no antibiotics have been used within 6 months before the study; (2) Normal blood glucose and body mass index.

Exclusion criteria

Exclusion criteria: Exclusion criteria for the case group were as follows: (1) Patients using hormone drugs; (2) Patients receiving radiotherapy and chemotherapy; (3) patients taking probiotics; Exclusion criteria for the control group were as follows: (1) People suffering from chronic metabolic diseases, chronic inflammation, autoimmune diseases, thyroid diseases and mental diseases; (2) Pregnant women.

Design outcomes

Primary

MeasureTime frame
Gut microbiota;

Countries

China

Contacts

Public ContactZemao Xing

Shenzhen Second People's Hospital

515039715@qq.com+86 13312918018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026